# Omni Cardio 510(k) Summary

This summary of $5 1 0 ( k )$ safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

The assigned 510(k) number is: k122291

# Company / Contact Person

Karen Lee   
Regulatory Affairs Specialist   
Thermo Fisher Scientific, Clinical Diagnostics Division 46360 Fremont Blvd.   
Fremont, CA 94538   
Phone: (510) 979-5000 x31814   
Fax: (510) 979-5422   
E-mail: karen.lee@thermofisher.com

Date Prepared August 29, 2012

# Regulatory Declarations

<table><tr><td rowspan=1 colspan=1>Common / Usual Name</td><td rowspan=1 colspan=1>MAS® OmniCARDIO</td></tr><tr><td rowspan=1 colspan=1>Trade / Proprietary Name</td><td rowspan=1 colspan=1>Thermo Scientific MAS® Omni-CARDIO</td></tr><tr><td rowspan=1 colspan=1>Classification Regulation</td><td rowspan=1 colspan=1>21 CFR 862.1660</td></tr><tr><td rowspan=1 colspan=1>Device Class</td><td rowspan=1 colspan=1>Class I, Reserved</td></tr><tr><td rowspan=1 colspan=1>Device Regulation Panel</td><td rowspan=1 colspan=1>Clinical Chemistry</td></tr><tr><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>JJY</td></tr></table>

# Intended Use $M A S ^ { \otimes }$ Omni-CARDIO

Thermo Scientific MAS® Omni-CARDIO™ is intended for use in the clinical laboratory as an assayed control serum for monitoring assay conditions related to cardiac and associated critical marker determinations.

7

# Legally Marketed Device to Which Equivalency is Claimed

The Thermo Scientific MAS® Omni-CARDIO is substantially equivalent to the previously cleared $M A S ^ { \otimes }$ Cardiolmmune TL (K040880) and MAS® Cardiolmmune XL (K061196).

# Device Description

Each MAS® Omni-CARDIO control kit is packaged in a plastic clamshell container with a product insert and value sheet. Each vial contains 3 mL of the control level in an amber glass bottle with black sterile caps. Kits are stored frozen at $\tt { - } 2 0 \%$

# Below are the different kit configurations:

<table><tr><td rowspan=1 colspan=1>Kit</td><td rowspan=1 colspan=1>Configuration</td></tr><tr><td rowspan=1 colspan=1>Level UL</td><td rowspan=1 colspan=1>6x 3mL</td></tr><tr><td rowspan=1 colspan=1>Level L</td><td rowspan=1 colspan=1>6 x 3 mL</td></tr><tr><td rowspan=1 colspan=1>Level 1</td><td rowspan=1 colspan=1>6x 3 mL</td></tr><tr><td rowspan=1 colspan=1>Level 2</td><td rowspan=1 colspan=1>6x 3 mL</td></tr><tr><td rowspan=1 colspan=1>Level 3</td><td rowspan=1 colspan=1>6 x 3 mL</td></tr><tr><td rowspan=1 colspan=1>Multi-Pack</td><td rowspan=1 colspan=1>Level 1 - 2 x 3 mLLevel 2 - 2 x 3 mLLevel 3 - 2 x 3 mL</td></tr><tr><td rowspan=1 colspan=1>Sample Pack</td><td rowspan=1 colspan=1>Level UL - 1 x 3 mLLevel L - 1 x 3 mLLevel 1 - 1 x 3 mLLevel 2 - 1 x 3 mLLevel 3 - 1 x 3 mL</td></tr></table>

$M A S ^ { \otimes }$ Omni-CARDIO control levels are provided in liquid form and are to be stored at $- 2 0 \%$ EY until the expiration date on the label: The control levels are prepared from human serum and contain the following constituents: Beta-Human Chorionic Gonadotropin (3-HCG), B-Type Natriuretic eptideP,CreatinKinase-MBCK-B -Dimer, DigitoxinHomocysin High Sensitivity C-Reactive Protein (hsCRP), Human Chorionic Gonadotropin (HCG), Myeloperoxidase (MPO), Myoglobin, N-Terminal Prohormone of Brain Natriuretic Peptide (NTproBNP), Procalcitonin (PCT), Total Creatine Kinase (CK), Troponin I, Troponin T.

# Stability Testing and Value Assignment Summary:

Accelerated testing was carried out for the evaluation lots at three elevated temperatures in order to support a shelf life storage temperature of $- 2 0 \%$ for 36 months. For each temperature tested, the required number of days of stress without failure was determined that would be equivalent to 36 months storage at $\mathsf { - } 2 0 ^ { \circ } \mathsf { C }$ .All analytes and lots tested met the minimum number of days for all temperatures tested in support of a shelf life clairm of 36 months frozen at $\mathsf { - } 2 0 ^ { \circ } \mathsf { C }$ . Real time testing at $\tt { \tt { - } 2 0 \tt { \circ } \tt { C } }$ is on-going.

Open and closed vial testing was carried out at $5 \%$ for all claimed analytes on the evaluation lots. Vials were thawed, mixed, and placed at $2 . 8 ^ { \circ } \mathsf { C }$ for the study. Vials were opened briefly each work day (open vial) or remained unopened (closed vial) until time of assay. Multiple timepoints were tested and the point of failure determined by linear regression analysis of the data. All analytes met the required claim of 15 days storage for both open and closed vial testing with the exception of Myoglobin and NT-ProBNP (10 days) and Homocysteine (5 days).

Value assignment testing was carried out to determine typical values that would be seen for the product across different analyzer platforms.Evaluation lots were sent to multiple sites, typically 2 or 3 lots per instrument platform, and assayed over 5 days in duplicate. For each analyte and analyzer combination, the data was averaged to determine a grand mean. Value assignment ranges were established at $+ 1 - 2 0 \%$ around the grand mean and were expanded if needed to

ensure the minimum and maximum values in the data set were within the established range.   
Vals or he valuation os all  withn the tablishee.

Omni Cardio - Target Ranges   

<table><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>Units</td><td rowspan=1 colspan=2>Level UL</td><td rowspan=1 colspan=2>Level L</td><td rowspan=1 colspan=2>Level 1</td><td rowspan=1 colspan=2>Level 2</td><td rowspan=1 colspan=2>Level 3</td></tr><tr><td rowspan=1 colspan=1>BNP 32</td><td rowspan=1 colspan=1>pg/mL</td><td rowspan=1 colspan=1>56</td><td rowspan=1 colspan=1>104</td><td rowspan=1 colspan=1>56</td><td rowspan=1 colspan=1>104</td><td rowspan=1 colspan=1>104</td><td rowspan=1 colspan=1>216</td><td rowspan=1 colspan=1>360</td><td rowspan=1 colspan=1>640</td><td rowspan=1 colspan=1>1400</td><td rowspan=1 colspan=1>2600</td></tr><tr><td rowspan=1 colspan=1>CK-MB</td><td rowspan=1 colspan=1>ng/mL</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>6.5</td><td rowspan=1 colspan=1>17.5</td><td rowspan=1 colspan=1>32.5</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>D-Dimer</td><td rowspan=1 colspan=1>ng/mL</td><td rowspan=1 colspan=2>Not Claimed</td><td rowspan=1 colspan=2>Not Claimed</td><td rowspan=1 colspan=1>190</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>700</td><td rowspan=1 colspan=1>1300</td><td rowspan=1 colspan=1>2100</td><td rowspan=1 colspan=1>3900</td></tr><tr><td rowspan=1 colspan=1>Digitoxin</td><td rowspan=1 colspan=1>ng/mL</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>8.1</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>8.1</td><td rowspan=1 colspan=1>8.5</td><td rowspan=1 colspan=1>13.5</td><td rowspan=1 colspan=1>15.0</td><td rowspan=1 colspan=1>29.0</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>62</td></tr><tr><td rowspan=1 colspan=1>Homocysteine</td><td rowspan=1 colspan=1>μmol/L</td><td rowspan=1 colspan=2>Not Claimed</td><td rowspan=1 colspan=2>Not Claimed</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>6.5</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>12.0</td><td rowspan=1 colspan=1>13.0</td><td rowspan=1 colspan=1>31.0</td></tr><tr><td rowspan=1 colspan=1>hsCRP</td><td rowspan=1 colspan=1>mg/L</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>0.80</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>0.80</td><td rowspan=1 colspan=1>1.30</td><td rowspan=1 colspan=1>3.20</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>6.5</td><td rowspan=1 colspan=1>7.0</td><td rowspan=1 colspan=1>13.0</td></tr><tr><td rowspan=1 colspan=1>MyeloperoxidaseMPO)</td><td rowspan=1 colspan=1>pmol/L</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>170</td><td rowspan=1 colspan=1>330</td><td rowspan=1 colspan=1>560</td><td rowspan=1 colspan=1>1040</td><td rowspan=1 colspan=1>2450</td><td rowspan=1 colspan=1>4550</td></tr><tr><td rowspan=1 colspan=1>Myoglobin</td><td rowspan=1 colspan=1>ng/mL</td><td rowspan=1 colspan=1>11.0</td><td rowspan=1 colspan=1>29.0</td><td rowspan=1 colspan=1>11.0</td><td rowspan=1 colspan=1>29.0</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>310</td><td rowspan=1 colspan=1>450</td><td rowspan=1 colspan=1>750</td></tr><tr><td rowspan=1 colspan=1>NT-proBNP</td><td rowspan=1 colspan=1>pg/mL</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>125</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>125</td><td rowspan=1 colspan=1>285</td><td rowspan=1 colspan=1>620</td><td rowspan=1 colspan=1>1600</td><td rowspan=1 colspan=1>3100</td><td rowspan=1 colspan=1>8400</td><td rowspan=1 colspan=1>15600</td></tr><tr><td rowspan=1 colspan=1>Procalcitonin</td><td rowspan=1 colspan=1>ng/mL</td><td rowspan=1 colspan=1>0.18</td><td rowspan=1 colspan=1>0.32</td><td rowspan=1 colspan=1>0.18</td><td rowspan=1 colspan=1>0.32</td><td rowspan=1 colspan=1>0.35</td><td rowspan=1 colspan=1>0.65</td><td rowspan=1 colspan=1>1.90</td><td rowspan=1 colspan=1>3.90</td><td rowspan=1 colspan=1>7.2</td><td rowspan=1 colspan=1>15.6</td></tr><tr><td rowspan=1 colspan=1>β-HCG</td><td rowspan=1 colspan=1>mlU/mL</td><td rowspan=1 colspan=2>Not Claimed</td><td rowspan=1 colspan=2>Not Claimed</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>12.0</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>270</td></tr><tr><td rowspan=1 colspan=1>Total CK</td><td rowspan=1 colspan=1>IU/L</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>78</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>78</td><td rowspan=1 colspan=1>91</td><td rowspan=1 colspan=1>169</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>420</td><td rowspan=1 colspan=1>780</td></tr><tr><td rowspan=1 colspan=1>Troponin I (Tnl)</td><td rowspan=1 colspan=1>ng/mL</td><td rowspan=1 colspan=1>0.025</td><td rowspan=1 colspan=1>0.080</td><td rowspan=1 colspan=1>0.100</td><td rowspan=1 colspan=1>0.280</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>0.45</td><td rowspan=1 colspan=1>0.75</td><td rowspan=1 colspan=1>1.50</td><td rowspan=1 colspan=1>10.0</td><td rowspan=1 colspan=1>20.0</td></tr><tr><td rowspan=1 colspan=1>Troponin T (TnT)</td><td rowspan=1 colspan=1>pg/mL</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>65</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>450</td><td rowspan=1 colspan=1>750</td><td rowspan=1 colspan=1>4800</td><td rowspan=1 colspan=1>7800</td></tr></table>

Comparison of Technological Characteristics   

<table><tr><td rowspan=1 colspan=1>Comparison</td><td rowspan=1 colspan=1>Proposed Device</td><td rowspan=1 colspan=1>Predicate1</td><td rowspan=1 colspan=1>Predicate 2</td></tr><tr><td rowspan=1 colspan=1>Proprietary Name</td><td rowspan=1 colspan=1>Thermo Scientific MAS®OmniCARDIO</td><td rowspan=1 colspan=1>MAS® Cardiolmmune TL</td><td rowspan=1 colspan=1>MAS® Cardiolmmune XL</td></tr><tr><td rowspan=1 colspan=1>510k Number</td><td rowspan=1 colspan=1>k122291</td><td rowspan=1 colspan=1>k040880</td><td rowspan=1 colspan=1>k061196</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Thermo Scientific MAS®Omni-CARDIO™ is intendedfor use in the clinicallaboratory as an assayedcontrol serum for monitoringassay conditions related tocardiac and associatedcritical markerdeterminations.</td><td rowspan=1 colspan=1>Cardiolmmune® TL isintended for use in theclinical laboratory as anassayed control serumsuitable for monitoring assayconditions in specific cardiacmarker determinations.</td><td rowspan=1 colspan=1>MAS® Cardiolmmune® XL isintended for use in theclinical laboratory as anassayed control serum formonitoring assay conditionsin specific cardiac markerdeterminations.</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Human Serum</td><td rowspan=1 colspan=1>Human Serum</td><td rowspan=1 colspan=1>Human Serum</td></tr><tr><td rowspan=1 colspan=1>Format</td><td rowspan=1 colspan=1>Frozen Liquid</td><td rowspan=1 colspan=1>Frozen Liquid</td><td rowspan=1 colspan=1>Frozen Liquid</td></tr><tr><td rowspan=1 colspan=1>Control Levels</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>4</td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=1>-20</td><td rowspan=1 colspan=1>-20°</td><td rowspan=1 colspan=1>-20°</td></tr><tr><td rowspan=1 colspan=1>Shelf Life</td><td rowspan=1 colspan=1>36 months</td><td rowspan=1 colspan=1>36 months</td><td rowspan=1 colspan=1>36 months</td></tr><tr><td rowspan=1 colspan=1>Open Vial Stability</td><td rowspan=1 colspan=1>15 days (2-8°C) exceptNT-ProBNP, Myoglobin (10days)Homocysteine (5 days)</td><td rowspan=1 colspan=1>30 days (2-8°C) exceptNT-ProBNP (10 days)</td><td rowspan=1 colspan=1>30 days (2-8°C) exceptCK-MB, Troponin-T, BNP32, NT-ProBNP (15 days)Myoglobin (5 days)</td></tr><tr><td rowspan=1 colspan=1>Closed Vial Stability</td><td rowspan=1 colspan=1>15 days (2-8°C) exceptProBNP, Myoglobin (10days)Homocysteine (5 days)</td><td rowspan=1 colspan=1>30 days (2-8°C)</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Analytes</td><td rowspan=1 colspan=1>BNP 32CK-MBD-DimerDigitoxinHomocysteinehsCRPMyeloperoxidase (MPO)MyoglobinNT-ProBNPProcatcitonin (PCT)bHCGTotal CKTroponin-I (Tnl)Troponin-T (TnT)</td><td rowspan=1 colspan=1>CK-MBDigitoxinhsCRPMyoglobinNT-ProBNPTroponin-I (Tnl)Troponin-T (TnT)</td><td rowspan=1 colspan=1>BNP 32CK-MBDigitoxinHomocysteinehsCRPMyoglobinNT-ProBNPTroponin-I (Tnl)Troponin-T (TnT)</td></tr></table>

# Conclusion

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.

Microgenics Corporation   
Thermo Fisher Scientific, Clinical Diagnostics Division c/o Karen Lee   
46360 Fremont Blvd.   
Fremont, CA 94538

Re: k122291 Trade Name: MAS® OmniCARDIO Regulation Number: 21 CFR $\ S 8 6 2 . 1 6 6 0$ Regulation Name: Quality Control Material (assayed and unassayed) Regulatory Class: Class I, reserved Product Codes: JJY . Dated: July 30, 2012 Received: July 31, 2012

Dear Ms. Lee:

We have reviewed your Section $5 1 0 ( \mathrm { k } )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class II (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with al the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/Medical   
Devices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance...

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm

Sincerely yours,

![](images/a182c697dbe57b9d485c5e7910f0ef337c8fad73b42fe76509df6fea10a211e1.jpg)

Courtney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# Indications for Use Statement

510(k) Number (if known) k122291

Device Name MAS® Omni CARDIO

# Indications For Use $M A S ^ { \otimes }$ Omni·CARDIO

Thermo Scientific $M A S ^ { \otimes }$ OmniCARDIO™ s intended or use n the clinical laboratoryas a assayed control serum for monitoring assay conditions related to cardiac and associated critical marker determinations.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

![](images/df65710f583af8f3c410566ad58405a56bcb37732e28914725d6ee17727b1de0.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

510(k) K122291